€13.70
Your prediction
Deciphera Pharmaceuticals Stock
Pros and Cons of Deciphera Pharmaceuticals in the next few years
Pros
Cons
Performance of Deciphera Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals | -0.720% | -2.128% | -4.531% | 5.023% | -6.091% | -63.298% | - |
| Ardelyx Inc. | 0.100% | -7.414% | -16.973% | 36.533% | 6.298% | -15.255% | - |
| Salarius Pharmaceuticals Inc. | 0.930% | 6.468% | -31.520% | -69.209% | -22.883% | -98.226% | -99.994% |
| Evolus Inc | -2.630% | -5.882% | -12.500% | 43.590% | 19.786% | 18.519% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Deciphera Pharmaceuticals (ticker: DCPH), a player in the Biotechnology & Medical Research industry, presents an intriguing financial profile. At first glance, its financial statements and subsequent ratios reveal a company in a precarious position with some inherent risks but also potential upside reflective of the sector it operates in. Generally, biotech firms like Deciphera engage in high-stakes research and development (R&D), which can burn through capital while pursuing breakthroughs with the promise of substantial future payoffs.
Liquidity and Cash Reserves: Deciphera has been maintaining a strong cash and short-term investment position over the past years. A steady cash reserve is critical in the biotech industry where R&D and regulatory approvals can take time.
Gross Profit: The gross profit shown in the income statements indicates that the company is able to generate revenue over and above the direct costs associated with its main operations. A positive gross profit is a good sign in a sector where many companies struggle to generate any revenue at all.
Comments
